# Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer

> **NCT00922129** · PHASE2,PHASE3 · WITHDRAWN · sponsor: **St. Joseph's Healthcare Hamilton**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Sirolimus (Rapamune)
- **DRUG:** Cyclosporin (Neoral) or Tacrolimus (Prograf)

## Key facts

- **NCT ID:** NCT00922129
- **Lead sponsor:** St. Joseph's Healthcare Hamilton
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2009-09
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study did not start up as planned.
- **Last updated:** 2014-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00922129

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00922129, "Effectiveness of Conversion to Sirolimus Versus Calcineurin Inhibitor (CNI) Reduction in Renal Transplant Patients With Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00922129. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*